当前位置: X-MOL 学术BMC Rheumatol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis.
BMC Rheumatology ( IF 2.1 ) Pub Date : 2019-12-16 , DOI: 10.1186/s41927-019-0096-1
Arata Nakajima 1, 2, 3 , Keiichiro Terayama 3 , Masato Sonobe 1 , Yasuchika Aoki 4, 5 , Hiroshi Takahashi 1 , Yorikazu Akatsu 1 , Junya Saito 1 , Shinji Taniguchi 1 , Manabu Yamada 1 , Ayako Kubota 6 , Koichi Nakagawa 1
Affiliation  

Background To verify whether serum levels of reactive oxygen metabolites (ROM) are predictive of future clinical remission in patients with rheumatoid arthritis (RA) receiving tocilizumab (TCZ) therapy. Methods A total of 46 patients with RA receiving TCZ therapy were enrolled in this study. Patients were divided into remission and non-remission groups based on disease activity score 28 (DAS28)-erythrocyte sedimentation rate (ESR) or clinical disease activity index (CDAI) at 52 weeks. Associations between serum levels of ROM, C-reactive protein (CRP), and matrix metalloproteinase-3 (MMP-3) at 4 and 12 weeks and the remission by DAS28-ESR and CDAI at 52 weeks were investigated. Results There were no significant differences in CRP and MMP-3 between DAS- or CDAI-remission and non-remission groups at 12 weeks. However, ROM in DAS-remission group were significantly lower than those in the non-remission group. For ROM, the area under the curve of the receiver operating characteristic curve was 0.735 and the cut-off value that distinguished DAS-remission group from non-remission group was 305.5 U. Carr (sensitivity: 70.0%, specificity: 72.2%). A multivariate logistic regression analysis revealed that ROM at 12 weeks was associated with DAS-remission at 52 weeks (odds ratio: 6.067, 95% confidence interval: 1.305-28.203). Conclusion Serum levels of ROM at 12 weeks during TCZ therapy may be predictive of DAS-remission at 52 weeks in patients with RA.

中文翻译:

托珠单抗治疗期间 12 周的血清活性氧代谢物水平可预测类风湿性关节炎患者 52 周的疾病活动评分缓解。

背景 验证血清活性氧代谢物 (ROM) 水平是否可预测接受托珠单抗 (TCZ) 治疗的类风湿关节炎 (RA) 患者未来的临床缓解。方法共纳入46例接受TCZ治疗的RA患者。根据52周时的疾病活动评分28(DAS28)-红细胞沉降率(ESR)或临床疾病活动指数(CDAI)将患者分为缓解组和非缓解组。研究了 4 周和 12 周时血清 ROM、C 反应蛋白 (CRP) 和基质金属蛋白酶 3 (MMP-3) 水平与 52 周时 DAS28-ESR 和 CDAI 缓解之间的关联。结果 DAS-或CDAI-缓解组与非缓解组在12周时CRP和MMP-3无显着差异。然而,DAS 缓解组的 ROM 显着低于非缓解组。对于 ROM,受试者工作特征曲线的曲线下面积为 0.735,区分 DAS 缓解组与非缓解组的临界值为 305.5 U.Carr(敏感性:70.0%,特异性:72.2%)。多变量逻辑回归分析显示,12 周时的 ROM 与 52 周时的 DAS 缓解相关(优势比:6.067,95% 置信区间:1.305-28.203)。结论 TCZ 治疗期间 12 周时的血清 ROM 水平可预测 RA 患者 52 周时的 DAS 缓解。735,区分 DAS 缓解组与非缓解组的临界值为 305.5 U. Carr(敏感性:70.0%,特异性:72.2%)。多变量逻辑回归分析显示,12 周时的 ROM 与 52 周时的 DAS 缓解相关(优势比:6.067,95% 置信区间:1.305-28.203)。结论 TCZ 治疗期间 12 周时的血清 ROM 水平可预测 RA 患者 52 周时的 DAS 缓解。735,区分 DAS 缓解组与非缓解组的临界值为 305.5 U. Carr(敏感性:70.0%,特异性:72.2%)。多变量逻辑回归分析显示,12 周时的 ROM 与 52 周时的 DAS 缓解相关(优势比:6.067,95% 置信区间:1.305-28.203)。结论 TCZ 治疗期间 12 周时的血清 ROM 水平可预测 RA 患者 52 周时的 DAS 缓解。
更新日期:2020-04-22
down
wechat
bug